Laboratory Monitoring of Tyrosinemia Type I with Nitisinone

Туре	of Evaluation	What it Measures	At Diagnosis	With Appropriate Treatment
CBC:			These results reflect aver	age results and may vary from child to child
	Hgb, Hct, WBC, plts	Complete Plead Count (CPC)	Possibly Low	Normal range
		Complete Blood Count (CBC)	FOSSIDIY LOW	Normal range
-	sinemia Markers (blood): alpha-fetoprotein	Liver Function	Very high	Normal range
				-
(3)	succinylacetone	Diagnosis of tyosinemia	Present	Absent
(4)	(delta-ALA dehydratase)*	Enzyme	Low	Normal range
Bloo	d Chemistries:			
(5)	amino acids (methionine, phenylalanine, tyrosine)	Metabolism of protein	Methionine: high Phenylalanine: high Tyrosine: high or normal	Methionine: normal range Phenylalanine: normal range Tyrosine: high (but <500 mcmol/L)
(6)	prothrombin time (PT)	Blood clotting	Elevated	Normal range
(7)	partial thromboplastin time (PTT)	Blood clotting	Elevated	Normal range
(8)	bilirubin	Jaundice	Possibly elevated	Normal range
(9)	ALT/AST	Liver Function	Possibly elevated	Normal range
(10)	GGT	Liver Function	Possibly elevated	Normal range
(11)	alkaline phosphatase	Bone formation	Possibly elevated	Normal range
(12)	BUN, creatinine	Kidney function	Possibly elevated	Normal range
Urine	Samples:			
(13)	succinylacetone	Diagnosis of tyosinemia	Present	Absent
(14)	(delta-aminoleuvulinic acid)*	A metabolite elevated in tyrosinemia	Elevated	Normal range
Rena	l Studies:			
(15)	renal ultrasound (nephromegaly)	Non-invasive view of kidneys	Possible dilation of kidneys	Normal size
Skeletal Evaluation:				
(16)	x-ray of wrist (rickets)	Non-invasive view of bones	Possible rickets	May resolve
CT Evaluation:				
(17)	abdominal CT (hepatocarcinoma)	Non-invasive view of liver	Possible 'nodules' seen	May resolve, or remain unchanged
Developmental Evaluation:				
(18)	Differential Ability Scale (DAS), WAIS-R, Stanford Binet, etc.	Intellectual development	N/A	Appropriate
(19)	Growth	Height, weight	Possibly delayed	Appropriate
Nutri	tional Evaluation			
` '	Nutrient Intake	Overall nutritional status	N/A	N/A
	r (optional)	The genetic changes that caused		
(21)	Mutation Analysis	tyrosinemia	N/A	N/A

^{*} Those children who were diagnosed after Orfadin became commercially available do not require these laboratory measurements. They are part of a research protocol only.